Gardasil recommended in EU countries
Sanofi Pasteur MSD, a joint venture between France's Sanofi-Aventis and the USA's Merck & Co, has welcomed the announcement that several European Union member states have added the vaccine Gardasil (human papillomavirus types 6, 11, 16 and 18) to their childhood immunization services. In Denmark, the National Board of Health has recommended the vaccine for all 12 year-old girls as well as introducing a two-year catch-up program which aims to vaccinate 13-15 year-old girls who have missed out.
In Spain, the vaccine manufacturer said that discussions between the competent national and regional authorities on how best to implement a catch-up program for adolescent girls and young women is ongoing. The country's Inter-Territorial Board approved the inclusion of Gardasil into the child vaccination calendar by a unanimous vote.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze